Retrospective evaluation of the Dutch pre-newborn screening cohort for propionic acidemia and isolated methylmalonic acidemia: What to aim, expect, and evaluate from newborn screening? by Haijes, H.A. (Hanneke A.) et al.
OR I G I N A L AR T I C L E
Retrospective evaluation of the Dutch pre-newborn
screening cohort for propionic acidemia and isolated
methylmalonic acidemia: What to aim, expect, and evaluate
from newborn screening?
Hanneke A. Haijes1,2 | Femke Molema3 | Mirjam Langeveld4 |
Mirian C. Janssen5 | Annet M. Bosch6 | Francjan van Spronsen7 |
Margot F. Mulder8 | Nanda M. Verhoeven-Duif1 | Judith J.M. Jans1 |
Ans T. van der Ploeg3 | Margreet A. Wagenmakers9 | M. Estela Rubio-Gozalbo10 |
Martijn C. G. J. Brouwers11 | Maaike C. de Vries12 | Janneke G. Langendonk9 |
Monique Williams3 | Peter M. van Hasselt2
1Section Metabolic Diagnostics, Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
2Section Metabolic Diseases, Department of Child Health, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht University,
Utrecht, The Netherlands
3Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands
4Department of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
5Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
6Department of Pediatrics, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
7Division of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen,
The Netherlands
8Department of Pediatrics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
9Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam,
The Netherlands
10Department of Pediatrics and Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands
11Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, Maastricht University Medical Center, Maastricht,
The Netherlands
12Department of Pediatrics, Radboud University Medical Center, Nijmegen, The Netherlands
Correspondence
Peter M. van Hasselt and Hanneke A.
Haijes, Wilhelmina Children's Hospital,
University Medical Center Utrecht,
Lundlaan 6, 3584 EA Utrecht, the
Netherlands.
Email: p.vanhasselt@umcutrecht.nl
Abstract
Evidence for effectiveness of newborn screening (NBS) for propionic acidemia
(PA) and isolated methylmalonic acidemia (MMA) is scarce. Prior to imple-
mentation in the Netherlands, we aim to estimate the expected health gain of
NBS for PA and MMA. In this national retrospective cohort study, the clinical
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course of 76/83 Dutch PA and MMA patients, diagnosed between January
1979 and July 2019, was evaluated. Five clinical outcome parameters were
defined: adverse outcome of the first symptomatic phase, frequency of acute
metabolic decompensations (AMD), cognitive function, mitochondrial compli-
cations, and treatment-related complications. Outcomes of patients identified
by family testing were compared with the outcomes of their index siblings. An
adverse outcome due to the first symptomatic phase was recorded in 46% of
the clinically diagnosed patients. Outcome of the first symptomatic phase was
similar in 5/9 sibling pairs and better in 4/9 pairs. Based on the day of diagno-
sis of the clinically diagnosed patients and sibling pair analysis, a preliminary
estimated reduction of adverse outcome due to the first symptomatic phase
from 46% to 36%-38% was calculated. Among the sibling pairs, AMD frequency,
cognitive function, mitochondrial, and treatment-related complications were
comparable. These results suggest that the health gain of NBS for PA and MMA
in overall outcome may be limited, as only a modest decrease of adverse out-
comes due to the first symptomatic phase is expected. With current clinical
practice, no reduced AMD frequency, improved cognitive function, or reduced
frequency of mitochondrial or treatment-related complications can be expected.
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1 | INTRODUCTION
Propionic acidemia (PA, OMIM #6060054) and isolated
methylmalonic acidemia (MMA, OMIM #251000,
#251100, #251110, #277400, and #277410) are caused by
enzyme and cofactor deficiencies involved in propionyl-
CoA breakdown. The clinical course usually starts with
an acute metabolic decompensation (AMD) in the neona-
tal period (early onset, EO) or thereafter (late onset,
LO).1 The first symptomatic phase frequently causes irre-
versible neurological damage, manifesting as movement
disorders in varying severity and/or psychomotor retarda-
tion. This neurological damage is often reflected by white
matter lesions and/or basal ganglia hyperintensities on
brain imaging. In addition, the clinical course is
characterised by frequent AMD, cognitive deficits, and
long-term complications.2
A diagnosis before the first symptomatic phase, feasi-
ble through newborn screening (NBS), could theoretically
prevent the neurological damage.3 However, the majority
of patients is symptomatic well before NBS results can be
available, limiting the potential gain.4,5 Four studies
described the potential additional value of NBS, but each
with limited sample sizes and follow-up time,6-9 resulting
in controversy about the potential effectiveness of NBS
for PA and MMA.
Many efforts have been made to achieve consensus
on which diseases are suitable for screening, both on a
global level by the World Health Organisation
(WHO)10,11 (Supplementary Notes S1) and on European
level.12-14 Despite these efforts, it is still debatable which
diseases to screen for and it is not clear on what criteria
decisions should be based, resulting in divergent conclu-
sions. Regarding PA and MMA, NBS implementation has
been recommended in the United States of America,15
but PA and MMA were not included in the European list
of 26 disorders to be considered for NBS expansion.13
Nevertheless, several European countries implemented
NBS for PA and MMA.5
In the Netherlands, the Health Council decided based
on the expected health gain for LO patients that NBS for
PA and MMA met the screening criteria and will start in
October 2019.16 NBS will be performed based on
increased C3-carnitine and increased C3/C2 carnitine
ratio, complemented with a second-tier test on increased
2-methylcitric acid and methylmalonic acid. As the heel
prick is performed within 3-7 days after birth, the aim is
to report a positive second-tier test within 11-21 days
after birth.
For the addition of new diseases to NBS, three WHO
criteria seem of particular importance: clearly defined
objectives (WHO#2), evidence for effectiveness (WHO#4)
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and careful evaluation (WHO#9)11 (Supplementary Notes
S1). To date, for PA and MMA, these three criteria are
not sufficiently met. Also, despite statements that good
long-term outcome is the ultimate goal and that monitor-
ing is necessary to evaluate NBS programmes, long-term
outcome is rarely monitored in a standardised manner.13
We performed a national retrospective cohort study
including 76/83 Dutch PA and MMA patients. We aim to
define which objectives could be attained with NBS
implementation. Hereto, we estimate the expected health
gain in the Netherlands by comparing siblings diagnosed
via family testing with their older index sibling. In addi-
tion, we explore how evaluation of NBS implementation
can be performed by assessing newly defined clinical out-
come parameters. Lastly, we use insights obtained from
studying this pre-NBS cohort to guide counselling and
surveillance of NBS cohorts.
2 | METHODS
2.1 | Patient inclusion and compliance
with ethics guidelines
In this nationwide retrospective cohort study, patients'
clinical records from all six Dutch metabolic centres were
analysed. Patients were eligible for inclusion if PA or
MMA was confirmed by enzymatic activity analysis or
mutation analysis of PCCA, PCCB, MUT, MMAA,
MMAB, MCEE, or MMADHC. Patients or their legal
guardians signed an informed consent form, approving
analysis of their clinical records, and publication of the
anonymous data, in agreement with institutional and
national legislation. The study was approved by the Ethi-
cal Committees of the University Medical Centers
Utrecht (17-490/C) and Rotterdam (MEC-2018-1312), on
behalf of all Ethical Committees of involved University
Medical Centers. All procedures followed were in accor-
dance with the ethical standards of these committees and
with the Helsinki Declaration of 1975, as revised in 2000.
2.2 | Data collection
Data collection was performed by two investigators (H.A.
H. and F.M.). Data were extracted from both paper and
electronic patient files. Data were collected from the first
symptomatic phase until the last follow-up visit. Data col-
lection was focused on patient and family characteristics,
outcome of the first symptomatic phase, AMD, hospital
admissions, cognitive and psychomotor development, and
long-term complications. All data were entered in the
OpenClinica open source software, version 3.12.2.
EO was defined as an episode of severely reduced
clinical condition starting in the first 28 days of life, and
LO as symptoms starting after 28 days of life.1 Patients
identified through family testing based on an affected
older (index) sibling were regarded a separate category.
2.3 | Outcome parameters
To evaluate clinical outcomes, five grouped outcome
parameters were defined (Supplementary Notes S2).
“Adverse outcome (AO) of the first symptomatic phase”
was categorised based on the presence of movement dis-
orders that developed during or right after the first symp-
tomatic phase, objectified during follow-up examinations
by paediatric neurologists and physiotherapists shortly
after the first symptomatic phase, and/or the presence of
basal ganglia hyperintensities or white matter abnormali-
ties detected at the first time of brain imaging after the
first symptomatic phase (Supplementary Notes S2).
“AMD frequency” was defined based on the frequency of
(impending) AMD requiring hospital admission per
patient year (PY) in the first 4 years of life, other than the
first symptomatic phase (Supplementary Notes S2). “Cog-
nitive function” was distinguished in three categories
based on neuropsychological test results, or in the absence
of neuropsychological test results on educational level or
professional employment17 (Supplementary Notes S2).
Long-term complications were divided into mitochondrial,
treatment-related, and miscellaneous complications.
Patients were categorised into six categories based on the
number of mitochondrial complications present at a cer-
tain age. These mitochondrial complications included
21 complications likely to be caused by mitochondrial fail-
ure2 (Supplementary Notes S2). Complications with poten-
tial treatment-related aetiology included decreased bone
mineral density (BMD), growth retardation, and obesity2
(Supplementary Notes S2). Growth retardation was defined
present when height to weight was less than −2 SD at any
moment during follow-up. Other complications, with no
evidence for a sole mitochondrial or treatment-related
aetiology, were regarded miscellaneous complications.
These complications included pes planovalgus, port-a-cath
infections, teeth enamel defects, urolithiasis, and gout.2
2.4 | Data-analysis
Each outcome parameter was evaluated in the complete
cohort, separate for both PA and MMA patients, and sep-
arate for both EO and LO patients. In addition, for all
AMDs age at decompensation, admission duration, need
for intensive care unit admission, and AMD triggers
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were evaluated. For each complication assessed, preva-
lence was calculated.
As a proxy for the potential health gain of NBS, all five
clinical outcome parameters were compared between
patients identified by family testing and their index sib-
lings. The expected health gain was calculated by extrapo-
lating findings of the sibling comparison on AO of the first
symptomatic phase to the entire cohort, if NBS would
have been implemented. Calculations were performed for
six possible days that definitive NBS results could become
available: day 0, 3, 7, 11, 15, and 21 after birth.
Assessment of risk factors for each outcome parame-
ter was performed by comparing disease types, for both
PA and MMA presentation types and, for MMA vitamin
B12 responsiveness.
All statistical analyses were performed in R program-
ming language. Results are expressed as either means or
medians with standard deviations and ranges for quanti-
tative data and as number and percentage for qualitative
data. Student's t tests were performed for quantitative
data and Fisher's exact tests for qualitative data. P-values
were adjusted according to the Bonferroni method when
multiple testing was performed, adjusted P-values <.05
were considered statistically significant. P-values solely
reported in the text for the assessment of risk factors of
clinical outcome parameters were calculated using Fish-
er's exact tests and were not adjusted, as no multiple test-
ing was performed.
3 | RESULTS
3.1 | Patient characteristics
Of all 83 PA and MMA patients in the Netherlands diag-
nosed between January 1979 and July 2019, 76 patients
were included. Five patients refused to participate and
clinical records of two deceased MMA patients could not
be retrieved. For nearly all patients, data were available
from the first symptomatic phase to the last moment of
follow-up. The cohort included 31 PA patients from
24 families and 45 MMA patients from 40 families.
Between 1 January 1998 and 31 December 2017, 46/76
patients (PA: n = 19, MMA: n = 27) were diagnosed, with
a median of 2 patients per birth year (range: 1-5). In this
period, 3 729 128 live births were registered, providing an
estimated incidence in the Netherlands of 1:81 000 for
PA and MMA combined, 1:196 000 for PA and 1:138 000
for MMA. Presentation type was EO in 29, LO in 34, fam-
ily testing in 12, and unknown in 1 patient (Table 1).
TABLE 1 Baseline characteristics of the Dutch cohort of PA and MMA patients
Propionic acidemia (n = 31) Methylmalonic acidemia (n = 45)
Presentation type Early onset n = 15; 48% Early onset n = 14; 31%
Late onset n = 8; 26% Late onset n = 26; 56%
Family testing n = 7; 23% Family testing n = 5; 11%
Unknown n = 1; 3%
Presentation age Early onset 6.05 ± 6.12 days Early onset 2.07 ± 1.77 days
Late onset 14.1 ± 22.9 years Late onset 1.41 ± 2.74 years
Family testing 0.07 ± 0.19 years Family testing 0.32 ± 0.72 years
Genotype PCCA n = 8; 26% MUT n = 26; 58%
PCCB n = 7; 23% MMAA n = 8; 18%
MMAB n = 7; 16%
No mutation analysis n = 16; 52% No mutation analysis n = 4; 9%
Enzyme activity 0.0-0.4 nmol/h/mg n = 10; 32%
0.5-2.0 nmol/h/mg n = 5; 16%
Not measured n = 16; 52%
Vitamin B12 responsiveness Responsive n = 21; 47%
Not responsive n = 24; 53%
Age at last follow-up 19.2 ± 15.1 years 17.3 ± 12.1 years
Mortality n = 7; 23% (4 EO, 1 LO, 2 family) n = 2; 4% (1 LO, 1 family)
Notes: Early onset: presentation ≤28 days of life. Late onset: presentation >28 days of life. Qualitative data are expressed as number and percentage,
quantitative data as mean ± SD.
Abbreviations: EO, early onset; family, family testing; LO, late onset.
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Clinical data of five PA sibling pairs and one trio, and
three MMA sibling pairs (n = 9) were available for sibling
comparison (Table S1). Two MMA patients identified
through family testing could not be compared with their
index siblings, because medical records of the index sib-
ling were not available.
Mutation analysis was available in 52/76 patients and
revealed 24 previously unreported mutations, including
7 mutations in PCCA, 5 in PCCB, 8 in MUT, 2 in MMAA,
and 2 in MMAB (Table S2). Pregnancy and delivery were
uncomplicated in the majority of the patients' mothers.
Birth weight of MMA patients was significantly lower
compared to PA patients, in line with previous reports1 (-
Table S3). In most patients, the first symptomatic phase
was characterised by lethargy and anorexia. Significantly
more LO patients presented with vomiting. Plasma
ammonia at presentation was significantly higher in EO
patients, resulting in significantly more EO patients
requiring dialysis (Table S4).
3.2 | Adverse outcome of the first
symptomatic phase
An AO of the first symptomatic phase was recorded in
36/76 (47%) of all patients and in 30/64 (47%) of the clini-
cally diagnosed patients (Figure 1). Movement disorders
were recorded in 24/36 patients. Basal ganglia hyper-
intensities were observed in 18, white matter abnormalities
in 14, and both in 6 patients. In 19/26 patients in whom
white matter abnormalities and/or basal ganglia hyper-
intensities were observed, brain imaging was performed
within 3 days to 6 months after the first symptomatic phase
and in 7/26 patients later in life (range: 9 months to
23 years). In three of these patients also a movement disor-
der was recorded, and in all seven patients the observed
abnormalities were considered to be long-existent based on
unchanged clinical symptoms and imaging characteristics.
In EO patients, an AO due to the first symptomatic
phase was either absent or, more often, mild, whereas in
LO patients most often no AO due to the first symptom-
atic phase was recorded. If an AO was recorded in LO
patients, it was either mild or severe, which is represen-
ted by a significant difference in mild AO due to the first
symptomatic phase in EO vs LO patients (Table 2 and
Figure S1). AO due to the first symptomatic phase tended
to be less frequent in patients identified through family
testing than in their siblings (better outcome of the first
symptomatic phase in 4/9 sibling pairs, similar in 5/9) (-
Table S1). Symptoms or signs present during the first
symptomatic phase, nor presentation type in PA or
MMA, nor vitamin B12 responsiveness in MMA was
associated with an increased risk for an AO (Table S5).
The expected health gain of NBS for PA and MMA in
the Netherlands was estimated based on the moment of
presentation of all EO and LO patients in this cohort and
based on analysis of sibling pairs (Figure 1, Table S1, and
Table 3). Theoretically, the earlier NBS results are avail-
able, the more patients could be protected from an AO
due to the first symptomatic phase (Figure 1 and Table 3).
In this cohort, NBS results available at day 0 of life could
have prevented an AO in 14 patients, reducing the per-
centage of an AO during the first symptomatic phase from
46% to 23%. NBS results available between day 11 and
21 could have prevented an AO in 6 or 5 patients, reducing
the percentage from 46% to 36%-38% (Table 3).
3.3 | AMD frequency
In total, 962 AMD requiring hospital admission were
reported. Hospitalisation duration was significantly
shorter in MMA than in PA patients. AMD triggers were
similar, with the exception of significantly more frequent
feeding problems in MMA patients and constipation in
PA patients (Table S6).
Among the sibling pairs, AMD frequency was similar
in 4/9 pairs. The index patients of 4/9 sibling pairs died
following an AMD, whereas all but one of the siblings
identified through family testing are still alive, although
currently only P6.3 survived his sibling in age (Table S1).
AMD frequency tended to be shifted towards a more
severe frequency in EO patients compared to LO patients
(Table 2 and Figure S1). Between PA and MMA patients,
no difference in AMD frequency was recorded. (Table S6).
Among PA patients, EO patients experienced signifi-
cantly more AMD/PY (P = .002) and among MMA
patients, vitamin B12 unresponsive patients experienced
significantly more AMD/PY (Table S6).
3.4 | Cognitive function
A total of 139 neuropsychological test results were
recorded in 46/76 patients, with a median of three tests
per patient (range: 1-10). In 17 patients, cognitive func-
tion was based on the patients' educational level and in
13 patients, cognitive function was not assessed (yet). An
IQ >90 was noted in 24/63 patients, an IQ between
60 and 90 in 20/63 patients, and an IQ <60 in 19/63
patients (Table S7).
Cognitive function was comparable among the sib-
ling pairs (similar in 3, better in 2, worse in 1, not
assessed in 3) (Table S1), as well as between EO and LO
patients (Table 2 and Figure S1). An IQ <60 was signifi-
cantly more prevalent in PA patients (Table S7). Among
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PA patients, EO was significantly associated with cogni-
tive function (IQ >90: EO 0%, LO 63%, P = .002).
Among MMA patients, presentation type nor vitamin
B12 responsiveness were associated with cognitive
function.
3.5 | Complications with potential
mitochondrial aetiology
Mitochondrial complications were present in 70/76
patients, and were mild in 30, moderate in 13, severe in
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 >28
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 >28
MMAA
PA, unclass.
MMA, unclass.
MMAB
MUT
PCCB
PA, unclass.
MUT
MMAA
MUT
PCCA
MMAA
PA, unclass.
MUT
PCCA
PCCA
PCCB
MUT
PA, unclass.
MUT
PCCA
PA, unclass.
PA, unclass.
PA, unclass.
MUT
MUT
PCCB
MMA, unclass.
MUT
MMAB
MMAA
PA, unclass.
PCCA
PCCB
PCCB
MMAA
MUT
PA, unclass.
MUT
PA, unclass.
MUT
MMAA
MMA, unclass.
PCCA
Mild AO
Severe AO
Death
n = 24
n =   4
n =   2
No AO
n = 34
n = 2
n = 3
n = 3
n = 5
n = 9
n = 4
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FIGURE 1 Age at onset and age at diagnosis for propionic acidemia (PA) and methylmalonic acidemia (MMA) patients. A, Patients
with early or late onset presentation. B, Patients identified through family testing. The y-axis depicts the patients, ordered on type of adverse
outcome, and age at diagnosis. The x-axis depicts the patient age in days, with a maximum of 28 days (early onset). Light grey circles depict
age at presentation, dark grey circles depict age at diagnosis, open circles depict in which patients the exact age at diagnosis is unknown. For
all ages at presentation and ages at diagnosis ≥28 days of age (late onset), the circles have been placed at 28 days. The vertical red solid lines
depict the potential moments NBS results could become available, in line with Table 3. On the left the severity of adverse outcomes
(AO) due to the first symptomatic phase are listed: no adverse outcome, mild, severe, or death due to the first symptomatic phase
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12, and very severe in 14 patients. One PA patient with
very severe mitochondrial complications died due to car-
diomyopathy. Prevalence of mitochondrial complications
was compared with the literature and was fairly compa-
rable for most complications2 (Table S7). For quite some
complications, especially for MMA, prevalence was here
assessed for the first time in a cohort study (Table S7).
Renal failure was significantly more prevalent among
MMA patients than among PA patients (Table S7).
For mitochondrial complications with acute onset,
age at onset was assessed (Table S7 and Figure 2). The
earliest manifestation of renal failure was already
reported at the age of 1.2 years in an MMAB patient and
in 5/20 patients age of onset was <6 years (2 MUT,
TABLE 2 Grouped outcome parameters according to presentation type
Early onset
(n = 29)
Late onset
(n = 34) P value
Bonferroni
correction
Adverse outcome of first symptomatic phase
No adverse outcome n = 11; 38% n = 23; 64% .024 NS
Mild adverse outcome n = 17; 59% n = 6; 21% .001 .006
Severe adverse outcome n = 0; 0% n = 4; 12% .118 NS
Death due to first presentation n = 1; 3% n = 1; 3% 1.000 NS
AMD frequency
None: no AMD in first 4 years n = 3; 10% n = 13; 38% .019 NS
Mild: >0.0 ≤ 0.5 AMD/PY n = 1; 3% n = 3; 9% .618 NS
Moderate: >0.5 ≤ 1.0 AMD/PY n = 2; 7% n = 2; 6% 1.000 NS
Severe: >1.0 ≤ 2.0 AMD/PY n = 6; 21% n = 3; 9% .280 NS
Very severe: >2.0 AMD/PY n = 11; 38% n = 5; 15% .045 NS
Death: during or due to AMD n = 3; 10% n = 1; 3% .326 NS
NA n = 3; 10% n = 7; 21% .319 NS
Cognitive function
Group 1: IQ >90 or regular education n = 4; 14% n = 15; 44% .013 NS
Group 2: IQ 60-90 or special education n = 10; 34% n = 8; 24% .407 NS
Group 3: IQ <60 or no education n = 10; 34% n = 5; 15% .081 NS
NA n = 5; 17% n = 6; 18% 1.000 NS
Mitochondrial complications
None n = 1; 3% n = 5; 15% .205 NS
Mild n = 6; 21% n = 19; 56% .005 .034
Moderate n = 5; 17% n = 5; 15% 1.000 NS
Severe n = 9; 31% n = 2; 6% .017 NS
Very severe n = 8; 28% n = 3; 9% .093 NS
Death n = 0; 0% n = 0; 0% 1.000 NS
NA n = 0; 0% n = 0; 0% 1.000 NS
Treatment-related complications
None n = 9; 31% n = 17; 50% .199 NS
Mild n = 10; 34% n = 13; 38% .798 NS
Severe n = 6; 21% n = 3; 9% .280 NS
Very severe n = 4; 14% n = 1; 3% .171 NS
NA n = 0; 0% n = 0; 0% 1.000 NS
Notes: Adverse outcome of first symptomatic phase: Adverse outcome of the first symptomatic phase. Early onset: presentation ≤28 days of life; Late onset:
presentation >28 days of life. Statistical significance was determined by Fisher's exact tests. All P-values were adjusted according to the Bonferroni method.
Adjusted P-values <.05 were considered statistically significant and are depicted in bold.
Abbreviations: AMD, acute metabolic decompensation; NA, not assessed; NS, not significant; PY, patient year.
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2 MMAB, and 1 unclassified). The first manifestation of
prolonged QTc interval was shortly after birth in PA, and
at 3.6 years in MMA. Cardiomyopathy in PA was noted
at 7.5 years, optic atrophy at 11.8 years in PA, and at
12.6 years in MMA (Table S7). Age at onset of hepato-
megaly, epilepsy, and sensorineural hearing loss ranged
from birth to 10 years, whereas most other complications
typically arose from late infancy to adolescence (Table S7
and Figure 2).
Mitochondrial complications were comparable among
sibling pairs (similar in 1, better in 4, and worse in 4)
(Table S1). LO patients were significantly more frequently
recorded to have only mild mitochondrial complications
than EO patients (Table 2 and Figure S1). PA patients
had more very severe mitochondrial complications than
MMA patients (Table S7), and all of these PA patients
were EO patients (EO 53%, LO 0%, P = .019). Among
MMA patients, mitochondrial complications were compa-
rable between EO and LO patients but the prevalence of
moderate to very severe mitochondrial complications was
significantly higher in vitamin B12 unresponsive patients
(unresponsive 63%, responsive 24%, P = .016).
EO for PA and vitamin B12 unresponsiveness for
MMA were also found to be significantly associated with
a higher risk for mitochondrial complications with acute
onset (Figure 3). In addition, EO in PA tended to be asso-
ciated with the occurrence of hepatomegaly, prolonged
QTc interval, psychoses, and sensorineural hearing loss
(Figure S2). Vitamin B12 unresponsiveness tended to be
associated with the occurrence of optic atrophy,
Pancreatitis
Psychosis
Opticus atrophy
Kidney failure
Stroke−like episode
Prolonged QTc interval
Cardiomyopathy
Sensorineural hearing loss
Hepatomegaly
Epilepsy
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 >35
Premature ovarian failure
Cardiomyopathy
Opticus atrophy
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Prolonged QTc interval
Kidney failure
Sensorineural hearing loss
Epilepsy
Hepatomegaly
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Age at onset (years)
(A) Propionic acidemia
(B) Methylmalonic acidemia
n = 7
n = 7
n = 11
n = 1
n = 4
n = 1
n = 7
n = 3
n = 6
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n = 20
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Family testingLate onsetEarly onset Vitamin B12 responsive Vitamin B12 unresponsive
FIGURE 2 Age at onset of mitochondrial complications with acute onset. A, Depicts propionic acidemia; B, depicts methylmalonic
acidemia. The y-axis depicts the mitochondrial complications with acute onset, ordered on median age at onset. The x-axis depicts patient
age in years, with a maximum of 35 years of age. For all ages >35 years, the circles have been placed at 35 years. The black vertical lines
depict the median age at onset. The filled circles and triangles depict the individual patient age at onset of a complication. Circles depict no
vitamin B12 responsiveness, triangles depict vitamin B12 responsiveness of methylmalonic acidemia patients. Blue circles and triangles
depict early onset, green circles and triangles depict late onset, orange circles and triangles depict diagnosis through family testing. Early
onset: presentation ≤28 days of life; late onset: presentation >28 days of life
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pancreatitis and prolonged QTc interval in MMA, and
was significantly associated with the occurrence of renal
failure (Figure S3). One of the first occurring mitochon-
drial complications with acute onset was hepatomegaly
(Figure 2). Intriguingly, hepatomegaly was significantly
associated with the onset of other mitochondrial com-
plications with acute onset later in life, for PA and
MMA as a group and for both PA and MMA separately
(Figure 3).
3.6 | Complications with potential
treatment-related aetiology
Reduced BMD was noted in 27, growth retardation in
21, and obesity in 16 patients. Treatment-related compli-
cations were absent in 33, mild in 28, severe in 9, and
very severe in 6 patients (Table S8).
Treatment-related complications were comparable
among sibling pairs (similar in 2, better in 5, and worse
in 2) (Table S1), as well as among EO and LO patients
(Table 2 and Figure S1), nor were there any differences
between PA and MMA, or among PA patients between
EO and LO patients (Table S8). Among MMA patients,
the rate of mild, severe, and very severe treatment-related
complications was significantly higher in vitamin B12
unresponsive patients (unresponsive 71%, unresponsive
33%, P = .017).
3.7 | Complications with miscellaneous
aetiology
A prevalence of 29% pes planovalgus, a feature so far only
described in MMA,18 was noted in PA. In one MMA and
one PA patient, urolithiasis was recorded. In both
patients, calculi developed due to hypercalciuria,
although dehydration, chronic acidotic state, and a low-
protein diet might have contributed. Two MMA patients
(MUT and MMAA) were found to have juvenile gout
(Table S8). The MMAA patient had chronic renal failure
when exhibiting gout, whereas the MUT patient did not.
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FIGURE 3 Factors associated with increased risks for mitochondrial complications with acute onset. Kaplan-Meier plots wherein the
y-axis depicts the cumulative percentage and the x-axis depicts patient age in years. Numbers at risk for the subgroups, indicating for how
many complications the patients are at risk, are depicted below the panels, in corresponding colours. Panels A and B demonstrate late onset
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unresponsiveness in orange for MMA. Panels D-F depicts the association of the presence of hepatomegaly to other mitochondrial
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10 HAIJES ET AL.
4 | DISCUSSION
4.1 | Expected health gain of NBS for PA
and MMA in the Netherlands (WHO#4)
Here, we present an extensive, nationwide cohort study,
describing the clinical course of 76/83 Dutch PA and
MMA patients. We demonstrated that the expected
health gain of introducing NBS for PA and MMA in the
Netherlands in overall outcome may be limited. Patients
can already present shortly after birth and even if
patients are diagnosed pre-symptomatically, they can still
develop an adverse outcome. We calculated an expected
reduction from 46% to 36%-38% AO due to the first symp-
tomatic phase and we consider it unlikely that NBS could
result in reduced AMD frequency, improved cognitive
function, or a reduced frequency of mitochondrial and
therapy-related complications.
These findings are in line with previous reports.
Although time to diagnosis is reduced in patients identi-
fied by NBS,9 NBS is unlikely to identify more than 59%-
72% of PA and MMA patients before the first symptom-
atic phase.8,9 One study described no decreased AMD fre-
quency, no better neurological outcome and no reduced
frequency of long-term complications in PA patients,8
although another study found that PA patients identified
by NBS had lower cardiac manifestations,9 but follow-up
time in these patients was limited. In MMA patients,
besides improved attainment of motor milestones and
reduced manifestations of movement disorders in vita-
min B12 unresponsive patients, NBS implementation did
not result in other improved outcome parameters.9
Thus, as evidence supporting improved outcomes if
treatment can be initiated in the asymptomatic phase is
limited, despite reasonable consensus on therapeutic strat-
egies for PA and MMA,19,20 it is questionable whether the
criterion regarding an accepted (effective) treatment for
patients with recognised disease is met (W&J#2). As a con-
sequence, it remains debatable whether the criteria
requesting effectiveness (WHO#4) and benefits outweigh
harm (WHO#10) are met (Supplementary Notes S1). We
advocate that the (now limited) health gain of NBS can
only be improved if treatment strategies are identified that
can effectively prevent AMD, cognitive impairment, and
mitochondrial complications, such as innovative therapies
aiming to increase enzyme activity.20
4.2 | Evaluation of NBS implementation
for PA and MMA (WHO#9)
Insight in NBS efficacy is still limited, due to factors com-
plicating proper evaluation, such as timing of evaluation.
Follow-up time of the four studies describing the poten-
tial additional value of NBS for PA and MMA was rela-
tively short, resulting in uncertainty when drawing
conclusions.6-9 We propose that these countries reassess
their NBS cohorts when a longer follow-up time is avail-
able. For the Netherlands, assuming a similar incidence
in the NBS cohort as in the here presented cohort, but
taking into account the slightly decreasing birth rate, it
will take at least till 2050 before an NBS cohort similar in
size and follow-up time as the pre-NBS cohort is available
for evaluation. More timely evaluation can only be
achieved by composing larger NBS cohorts through data
sharing initiatives, within Europe or worldwide.
Even if timing of evaluation is adequate, proper evalua-
tion of the presumed effect of NBS remains challenging
given the many factors that can influence the clinical
course of PA and MMA. This includes genotypic factors as
mutation type, residual enzyme activity, and vitamin B12
responsiveness (MMA). Also, a high variability in clinical
management existed between the different metabolic cen-
tres and metabolic physicians (data not shown). Next, com-
pliance of parents and patients to clinical management and
disease insight could influence clinical outcomes. More-
over, pre-NBS cohorts are diagnosed and treated in the era
before NBS cohorts, with NBS cohorts taking advantage of
general advances in clinical care, and possibly increased
insights and improved therapies for PA and MMA patients.
To aid evaluation of NBS efficacy, we suggest the five
clinical outcome parameters here presented and we advo-
cate the introduction of continuation and stop criteria.
We propose that NBS for PA and MMA should be contin-
ued when it results in a statistically significant and clini-
cally relevant reduction of AO due to the first
symptomatic phase, and that it should be stopped other-
wise. While based on our results, NBS may be unlikely to
result in reduced AMD frequency, improved cognitive
function, and reduced mitochondrial complications,
these outcome parameters should be assessed to gain
insight in the effects of improved treatment strategies. If
NBS would unexpectedly result in improvement of these
parameters, this would be a supportive argument to con-
tinue NBS. NBS evaluation should also include assess-
ment of treatment-related complications, to gain
knowledge regarding risks and harm of screening.
In NBS cohorts, patients in whom the disease is mild
and who would not become symptomatic during infancy,
could be detected as has been reported in Japan, where a
10 times higher incidence of PA was found during prepa-
ratory studies for NBS implementation.21 These mildly
affected patients will probably be treated according to the
current treatment guidelines,19 inducing a risk for devel-
oping treatment-related complications. One could advo-
cate that these patients should not be treated in order to
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prevent treatment-related complications. However, in
our cohort, two PA patients presented at 48 and 56 years
of age with cardiomyopathy as first presenting
symptom,22 indicating that even in very mild, untreated
patients, mitochondrial complications can still occur. It is
presently unknown whether earlier initiation of adequate
treatment could have prevented this complication. Even
if this would alter the clinical course, it is questionable
whether these patients should be exposed to life-long pro-
tein restriction, to prevent complications occurring well
into adulthood. We consider overtreatment of mildly
affected patients, which might or might not develop late
complications,21,22 a serious risk of NBS.
4.3 | Lessons learned from the pre-NBS
cohort, to guide follow-up of NBS cohorts
We demonstrated that mitochondrial complications with
acute onset can already develop before monitoring
should be initiated according to recent guidelines19 and
we thus propose to adapt these guidelines. Specifically,
we suggest to assess renal function in patients with MUT
and MMAB type MMA from 1 year of age, to regularly
check QTc intervals in PA and MMA patients starting at
birth, and to maintain yearly cardiac ultrasounds and
ophthalmologic assessments from 6 years onwards.
Importantly, as we demonstrate that hepatomegaly is
associated with the occurrence of other acute onset mito-
chondrial complications later in life, we advise to per-
form physical examination to check for hepatomegaly
during every outpatient visit starting at birth, to be able
to study the relevance of this finding. Lastly, we advocate
awareness of all complications assessed in this cohort,
including rarely described complications as exercise intol-
erance, acute psychosis, premature ovarian failure, pes
planovalgus, gout, and urolithiasis.
For surveillance and counselling of patients in NBS
cohorts, we stress the importance to take into account
disease severity. For MMA patients, we demonstrated
that vitamin B12 unresponsiveness increases the risk of a
higher AMD frequency, more mitochondrial complica-
tions, and more treatment-related complications. This is
in line with previous reports that demonstrate that vita-
min B12 unresponsiveness is associated with a decreased
survival rate in EO patients, a higher frequency of AMD,
an increased rate of developmental delay in EO patients,
and an increased rate of disability.23 In addition, a ten-
dency towards an increased rate of chronic renal failure
has been reported.24 For PA patients, EO is associated
with a higher risk for an AO of the first symptomatic
phase, a higher AMD frequency, more severe cognitive
impairment, and more mitochondrial complications.
While this still holds true for patients that are symptom-
atic before NBS results are available, presentation type
will be unknown for PA patients diagnosed via NBS, com-
plicating surveillance, and counselling of these patients.
This augments the need for systematic determination of
propionyl-CoA carboxylase activity in PA patients and
illustrates the imminent need for a metabolic marker that
can predict the risks for AMD frequency, cognitive func-
tion, and mitochondrial complications.25,26
We could not identify specific genotype-phenotype
correlations due to the variation of the identified muta-
tions. However, we did note that although patients with
MMAB type MMA are generally reported to be vitamin
B12 unresponsive,19 6/7 of our MMAB patients were
responsive. In five of these, we identified the MMAB
c.556C>T missense mutation in either homozygous or
heterozygous fashion (Table S2). We speculate that this
mutation might be related to the observed vitamin B12
responsiveness of MMAB patients, but we cannot prove
this hypothesis.
4.4 | Limitations and strengths
We note a few limitations. First, due to the retrospective
nature of this study and variable follow-up schedules,
missing data could have affected the reliability of the ana-
lyses. We expect missing data to be random and consider
it unlikely to have resulted in confounding. Nevertheless,
to facilitate reliable analyses and conclusions on NBS
effectivity, we advocate precise and structured prospec-
tive follow-up of NBS cohorts. Minimum requirements
for evaluation are listed in Table S9. Centres participating
in data-sharing initiatives should agree on the items to be
recorded and on the timing of diagnostics studies (-
Table S9). Second, sample size of the sibling comparison
is limited, hampering solid conclusions on the expected
health gain of NBS for PA and MMA, but consolidating
the urge for thorough assessment of NBS cohorts. The
potential health gain might have been overestimated
(a) due to the unknown number of EO patients that died
undiagnosed, (b) since families with an index child are
prepared for the diagnosis, and can minimise the risk for
AMD more efficiently than families from individuals
identified by NBS, and (c) since calculations were per-
formed with a potential overestimation of AO due to the
first symptomatic phase, as we assumed that all observed
brain imaging abnormalities were caused by the first
symptomatic phase instead of being caused by AMD
occurring later in life (and thus under treatment). Con-
versely, the potential health gain of NBS might have been
underestimated as the clinical course between siblings
may vary and it is not known whether the sibling
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diagnosed through family testing would have stayed in
the same condition if diagnosed later in life.
Important strengths of our study are that we provide
a comprehensive overview of a nationwide cohort span-
ning over four decades, by systematically assessing nearly
all PA and MMA patients in the Netherlands in great
detail. We designed five clinical outcome parameters to
guide evaluation of implementation NBS and we provide
an extensive description of a pre-NBS cohort to compare
NBS cohorts with. Moreover, due to the systematic
assessment of AMD, complications, and risk factor analy-
sis, we were able to establish recommendations regarding
surveillance and counselling of NBS cohorts. Lastly, con-
tinuation and stopping criteria for NBS were provided, as
well as minimum requirements for follow-up of NBS
cohorts to facilitate data sharing initiatives.
5 | CONCLUSIONS
The objective of NBS for PA and MMA in the Netherlands
is to protect LO patients from irreversible neurological dam-
age due to the first symptomatic phase. Implementation in
the Netherlands may result in a reduction of AO due to the
first symptomatic phase from 46% to 36%-38%, if NBS
results become available between day 11 and 21. We con-
sider reduced AMD frequency, improved cognitive function,
and reduced mitochondrial and treatment-related complica-
tions unlikely given the currently available therapies.
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